Tiger Brokers

BUZZ-CSL's Memo deal signals new R&D philosophy, Jefferies says

Reuters
Yesterday
BUZZ-CSL's Memo deal signals new R&D philosophy, Jefferies says

** Jefferies says Australia's CSL CSL.AX sees its new agreement with Switzerland-based Memo Therapeutics as "evidence" that the biotech major is now focusing on development by buying assets into its pipeline

** Memo on Monday said it entered into a collaboration and option agreement with CSL for development of recombinant polyclonal IgG technology, a method used to clone antibodies

** Jefferies notes CSL is looking to reenergise its research function in the longer term; however, flags it will likely take time, given the nature of R&D

** Brokerage adds Memo deal could help with CSL's product growth in the medium term, following co's VarmX deal last year

** CSL up 4.5% so far this year, as of last close

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10